Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

Industry groups have lined up on opposite sides of Illinois legislation aimed at providing patient access to discount ...

Shares of Tempus AI ( TEM -18.07%) are falling on Wednesday. One of Cathie Wood's largest holdings, the company's stock ...

Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for ...

An investment management firm known for short-selling the stocks it speaks against is now targeting a high-risk, high-reward ...

Ericsson said that the new AI infra will support compute-intensive AI tasks, including the training of specialized AI models.

There is decreased risk of in-hospital mortality in patients that receive minimally invasive surgery following nontraumatic intracerebral hemorrhage.

An extension trial revealed that long-term anifrolumab treatment improved health status and health-related quality of life in ...

R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.

About half of patients with asthma on tezepelumab had discontinued their daily maintenance oral corticosteroid doses by 52 ...

AstraZeneca (AZN) stock in focus as its antibody drug Imfinzi gains EU panel support for treating muscle-invasive bladder ...